Document is current
Any future updates will be listed below
-
Authors
Tian, Jun
Chen, Jonathan H.
Chao, Sherry X.
Pelka, Karin
Giannakis, Marios https://orcid.org/0000-0001-9012-6982
Hess, Julian https://orcid.org/0000-0003-1387-4009
Burke, Kelly https://orcid.org/0000-0003-2187-0147
Jorgji, Vjola
Sindurakar, Princy
Braverman, Jonathan
Mehta, Arnav
Oka, Tomonori https://orcid.org/0000-0001-7362-3207
Huang, Mei
Lieb, David
Spurrell, Maxwell
Allen, Jill N.
Abrams, Thomas A.
Clark, Jeffrey W. https://orcid.org/0000-0001-9524-3600
Enzinger, Andrea C.
Enzinger, Peter C.
Klempner, Samuel J. https://orcid.org/0000-0002-4062-0808
McCleary, Nadine J. https://orcid.org/0000-0003-2377-8301
Meyerhardt, Jeffrey A.
Ryan, David P.
Yurgelun, Matthew B. https://orcid.org/0000-0002-6184-9273
Kanter, Katie https://orcid.org/0000-0002-5778-9984
Van Seventer, Emily E.
Baiev, Islam
Chi, Gary
Jarnagin, Joy
Bradford, William B. https://orcid.org/0000-0003-4752-2677
Wong, Edmond https://orcid.org/0000-0001-6037-7377
Michel, Alexa G.
Fetter, Isobel J. https://orcid.org/0000-0002-6021-2713
Siravegna, Giulia
Gemma, Angelo J.
Sharpe, Arlene https://orcid.org/0000-0002-9736-2109
Demehri, Shadmehr https://orcid.org/0000-0002-7913-2641
Leary, Rebecca
Campbell, Catarina D. https://orcid.org/0000-0002-3863-9841
Yilmaz, Omer
Getz, Gad A. https://orcid.org/0000-0002-0936-0753
Parikh, Aparna R. https://orcid.org/0000-0002-5245-7841
Hacohen, Nir https://orcid.org/0000-0002-2349-2656
Corcoran, Ryan B. https://orcid.org/0000-0001-8173-5778
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA127003, U54CA224068)
EIF | Stand Up To Cancer (SU2C-AACR-DT22-17)
- License Information
-
More Information
Article History
Received: 12 June 2022
Accepted: 12 December 2022
First Online: 26 January 2023
Competing interests
: S.X.C. is an employee of Google Ventures. M.G. receives research funding from Servier and Janssen. A.M. has served a consultant/advisory role for Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Flare Therapeutics, venBio Partners, BioNTech, Rheos Medicines and Checkmate Pharmaceuticals; is an equity holder in Asher Biotherapeutics and Abata ThPerapeutics; and has a sponsored research agreement with Bristol Myers Squibb and Olink Proteomics. P.C.E. is/has been a consultant and has received honoraria from ALX Oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint Medicines, Chimeric Therapeutics, Celgene, Coherus, Daiichi-Sankyo, Five Prime, Ideaya, Istari, Legend, Lilly, Loxo, Merck, Novartis, Ono, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor and Zymeworks. S.J.K. has served a consultant/advisory role for Astellas, Merck, Bristol Myers Squibb, Daiichi-Sankyo, Pieris, AstraZeneca, Natera, Eli Lilly, Mersana and Sanofi-Aventis. S.J.K. owns stock in Turning Point Therapeutics. J.A.M. has served as an advisor/consultant to Merck Pharmaceutical and COTA Healthcare. M.B.Y. receives research funding from Janssen Pharmaceuticals. C.D.C. is an employee and shareholder of Novartis. N.H. receives research funding from Bristol Myers Squibb, has equity in BioNTech and advises and has equity in Related Sciences/Danger Bio. R.B.C. has received consulting or speaking fees from Abbvie, Amgen, Array Biopharma/Pfizer, Asana Biosciences, Astex Pharmaceuticals, AstraZeneca, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Cogent Biosciences, Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, LOXO, Merrimack, Mirati Therapeutics, Natera, Navire, Nested Therapeutics, N-of-one/Qiagen, Novartis, nRichDx, Remix Therapeutics, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Syndax, Tango Therapeutics, Taiho, Theonys, Warp Drive Bio and Zikani Therapeutics; holds equity in Avidity Biosciences, C4 Therapeutics, Cogent Biosciences, Erasca, Kinnate Biopharma, Interline Therapeutics, Nested Therapeutics, nRichDx, Remix Therapeutics, Revolution Medicines and Theonys; is a cofounder, equity holder and board member of Alterome Therapeutics; and has received research funding from Asana, AstraZeneca, Lilly, Novartis and Pfizer. The remaining authors declare no competing interests.
